This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Byetta.
Therapeutic Indication
### Therapeutic indication Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: - metformin; - sulphonylureas; - thiazolidinediones; - metformin and a sulphonylurea; - metformin and a thiazolidinedione; in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.
Therapeutic Area (MeSH)
ATC Code
A10BJ01
ATC Item
exenatide
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| exenatide | N/A | 艾塞那肽 |
EMA Name
Byetta
Medicine Name
Byetta
Aliases
N/A